New Schizophrenia Drug Cobenfy (Xanomeline and Trospium Chloride) Gets FDA Approval
The U.S. Food and Drug Administration (FDA) has approved Cobenfy (xanomeline and trospium chloride) to treat schizophrenia in adults, offering the first new treatment in decades for the psychiatric disorder. “This approval offers a new alternative to the antipsychotic medications people with schizophrenia have previously been prescribed,” Tiffany Farchione, MD, director of the division of […]